Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM versus LONOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM versus LONOX.
IMODIUM vs LONOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a peripheral mu-opioid receptor agonist that inhibits peristalsis and prolongs transit time by reducing smooth muscle motility in the gastrointestinal tract. It also increases anal sphincter tone and decreases secretion, leading to reduced stool frequency and increased consistency.
Loperamide is an opioid receptor agonist that acts on mu-opioid receptors in the myenteric plexus of the large intestine, inhibiting peristalsis and prolonging transit time. It also reduces colonic water and electrolyte secretion, enhancing fluid and electrolyte absorption. Loperamide has low systemic bioavailability due to extensive first-pass metabolism and is not significantly absorbed into the central nervous system due to P-glycoprotein efflux transport.
4 mg orally initially, followed by 2 mg after each unformed stool, not exceeding 16 mg/day. For chronic diarrhea: 4-8 mg/day in divided doses. Max 16 mg/day.
1-2 mg orally every 6 hours as needed for diarrhea; maximum 8 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 10.8 h). In patients with hepatic impairment, half-life may be prolonged, requiring dose adjustment.
Terminal half-life 12-15 hours; prolonged (up to 30 h) in elderly and renal impairment.
Primarily fecal (90-95% as unchanged drug and glucuronide conjugates), renal (<2% unchanged, ~10% as metabolites). Biliary excretion is the major route for conjugated metabolites.
Primarily renal (60-70% as unchanged drug and active metabolite); biliary/fecal ~20%.
Category C
Category C
Antidiarrheal
Antidiarrheal